The effects of body weight loss and gain on arterial hypertension control: an observational prospective study

Peter Sabaka1*, Andrej Dukat1, Jan Gajdosik1, Matej Bendzala1, Martin Caprn da1 and Fedor Simko2

Abstract

Background: Body weight changes are associated with significant variations in blood pressure (BP). Body mass modifications may, therefore, influence hypertension control in primary care.

Methods: Patients with a history of essential arterial hypertension were observed for 12 months. Anthropometric data and clinical BP were evaluated at the time of the recruitment and after 12 months of follow-up. The association between (body mass index) BMI change and BP control was analyzed by logistic regression.

Results: Sixteen thousand five hundred and sixty-four patients were recruited, while 13,631 patients (6336 men; 7295 women) finished the 1-year follow-up. In obese patients, a BMI decrease by at least 1 kg/m² was negatively associated with uncontrolled hypertension at the end of the follow-up (men \(p < 0.0001, OR = 0.586, 0.481–0.713\), women \(p < 0.001, OR = 0.804, 0.636–0.997\)). A similar association was observed in overweight patients (men \(p < 0.05, OR = 0.804, 95\% CI: 0.636–0.997\), women \(p < 0.05, OR = 0.730, 95\% CI: 0.568–0.937\)). A BMI increase of at least 1 kg/m² was associated with a significantly higher odd of uncontrolled hypertension in obese (men \(p < 0.001, OR = 1.471, 1.087–1.991\), women \(p < 0.001, OR = 1.422, 1.104–1.833\)) and overweight patients (men \(p < 0.0001, OR = 1.901, 95\% CI: 1.463–2.470\), women \(p < 0.0001, OR = 1.647, 95\% CI: 1.304–2.080\)).

Conclusions: Weight loss is inversely associated and weight increase is positively associated with the probability of uncontrolled hypertension in obese and overweight hypertensives.

Keywords: Obesity, Weight loss, Weight gain, Arterial hypertension

Background

Arterial hypertension is a major global public health problem. It is estimated that more than 1 billion people suffer from arterial hypertension and its prevalence is expected to rise in the coming decades [1]. Effective blood pressure (BP) control leads to regression of blood pressure-induced organ damage and reduction of cardiovascular risk [2–5]. Despite the well-recognized negative impact of arterial hypertension on cardiovascular prognosis, its control is regarded as very poor worldwide. The proportion of arterial hypertension patients with well-controlled BP is lower than 50% in most developed countries [6]. Another serious public health problem is the rising burden of overweight and obesity prevalent in more than one-third of the world’s population [7]. In developed countries like USA, the prevalence of obesity and overweight is estimated to be as high as 66% [8].

There is a large body of evidence suggesting that the risk of developing arterial hypertension and body weight (BW) increase/obesity is mutually interdependent [9–17]. The relationship between obesity and hypertension has been described as early as in 1923 [16]. However, decisive evidence emerged much later in the Framingham Heart Study, where the risk of developing arterial hypertension was observed to be approximately two-times higher in the obese population [17]. Later, it was observed that there is a linear association between BW and BP and that every 4.5 kg increase in body weight...
results in an increase of 4 mmHg in systolic blood pressure (SBP) [9]. On the other hand, weight loss results in a decrease in both SBP and diastolic BP (DBP) [11, 12].

Although weight reduction is recommended in the guidelines as an essential part of non-pharmacological management of hypertension, it is often neglected by both patients and primary care physicians [18]. Thus, the relevance and effectiveness of weight reduction in the management of arterial hypertension in daily clinical practice is still obscure.

Since weight increase is associated with increase in systolic and diastolic blood pressure, we hypothesize that increase in weight may impair the effectiveness of arterial hypertension therapy and could result in higher proportion of patients with uncontrolled hypertension in primary care. We conducted prospective observational study in which the primary goal was to assess the presence of uncontrolled hypertension at the end of the 1-year follow-up period and to assess an effect of weight increase and decrease on the uncontrolled hypertension as a primary endpoint.

Methods
We conducted partial data analysis from the MIRROR Slovakia Study, which was a nation-wide prospective observational study. The primary goal of the study was to assess the mode and efficiency of antihypertensive therapy in primary care during a 1-year follow-up of patients with known history of essential arterial hypertension. The subanalysis focused on the relationship between BMI changes and the level of hypertension control during the 1-year follow-up. Its primary goal was to assess the effect of weight increase and decrease on the uncontrolled hypertension as a primary endpoint. Patients in the MIRROR Slovakia Study were recruited proportionally from all parts of Slovakia by general practitioners and internists. They had medical histories of arterial hypertension, regardless on the level of hypertension control, and were older than 18 years. The exclusion criteria included a history of oncologic disease except total remission, pregnancy, thyrotoxicosis, a history of hypercorticism or therapy by corticoids, liver cirrhosis, malabsorption syndrome, and end-stage kidney disease. All patients signed an informed consent. At the recruitment and 1-year follow-up visits, the weight and height of the volunteers were obtained. Body mass index (BMI) was calculated as the BW in kilograms divided by the square of the height in meters. BP was measured by a certified automated sphygmomanometer after 5 min of rest in a sitting position on both arms three times, separated by 1 min interval. The mean value (of the three values taken) for each arm was calculated, and the higher mean value was used as definitive clinical BP. The target values for hypertension control were determined according to the 2013 European Society of Cardiology/European Society of Hypertension (ESC/ESC) guidelines [18]. Uncontrolled hypertension (used as primary endpoint for statistical analysis) was defined as clinical BP ≥ 140/90 mmHg, in patients with diabetes mellitus ≥ 140/80 mmHg and in elderly patients of over 80 years of age ≥ 150/90 mmHg. Obesity was defined as BMI ≥ 30 kg/m² and overweight as BMI of 25.0–29.9 kg/m². Significant weight reduction was defined as a decrease in BMI by at least 1 kg/m² and significant weight increase as an increase in BMI by at least 1 kg/m².

During the follow-up, the general practitioners and internists were free to change the pharmacologic anti-hypertensive therapy and/or recommend regime and diet changes; however they were instructed to adhere to recommendations of ESC/ESH guidelines and were also strictly instructed to provide the same level of medical attention to each patient [18]. According to observational design, investigators did not interfere with pharmacological and non-pharmacological therapy. To assess the potency of the pharmacological therapy between groups, the doses of the antihypertensive drugs were obtained by questionnaire. The doses were expressed as the proportion of doses in mg to the minimal effective doses as defined by the State Institute for Drug Control [19].

Statistical analysis
The descriptive data were provided as mean ± standard deviation. The statistical significance of the differences in the means of quantitative variables was assessed using ANOVA with Tukey posts hoc test. Normal distribution of quantitative variables was verified using Kolmogorov–Smirnov test. Qualitative variables were compared using Chi-square test. The statistical significance of the association between BMI change and arterial hypertension control status at the end of the follow-up (uncontrolled hypertension represented the primary endpoint) was assessed using binary logistic regression analysis. Age, baseline systolic and diastolic blood pressure, creatinine, and number of minimal effective doses of antihypertensive drugs at the beginning and at the end of the follow-up were included in the analysis as possible confounders. Cohorts with no significant BMI change were used as reference groups for test purposes. Differences with p values of less than 0.05 were considered as statistically significant. For the statistical analysis, the SPSS version 20 of Windows was used.

The study was approved by an ethical committee of Ministry of Health of Slovak Republic.
Results

Sixteen thousand five hundred and sixty-four patients were recruited, while 13,631 patients (6336 men; 7295 women) finished the 1-year follow-up and their data were available for analysis. Eight hundred and twenty-seven patients died and 2106 patients were lost to follow-up. At the end of the follow-up, 4162 (65.7%) men had no significant BMI change; 1489 (23.5%) had BMI decreased; and 685 (10.8%) had BMI increased and of women 4651 (63.8%) had no significant BMI change; 1634 (22.4%) had BMI decreased; and 1010 (13.8%) had the BMI decreased according to study criteria. The baseline characteristics of the cohorts are displayed in Table 1. At the baseline, there were no significant differences in patient cohorts regarding age, BMI, plasmatic creatinine concentration, and diabetes mellitus prevalence (Table 1). In systolic blood pressure and diastolic blood pressure, very small but statistically significant differences were observed (Table 1), and these variables were included in the later analysis as possible confounders.

In men, obesity and overweight were positively associated with the presence of uncontrolled hypertension in men, at the baseline. Hypertension was not sufficiently controlled in 51.2% of men with BMI < 25 kg/m², 56.1% of overweight men, and 61.4% of obese men (Table 2). In women, there was also a significant difference between the proportion of uncontrolled hypertension in obese women (60.9%) and in women with BMI < 25 kg/m² (54.2%) but not between overweight women and women with BMI < 25 kg/m² (Table 2).

Table 2 Association between uncontrolled hypertension and obesity/overweight at the baseline

| BMI at the baseline | N | Uncontrolled (%) | OR | 95% CI | p    |
|---------------------|---|-----------------|----|--------|------|
| Men BMI 25–29.9     | 3029 | 56.1 | 1.174 | 1.016–1.356 | < 0.0001 |
| Men BMI ≥ 30        | 2423 | 61.4 | 1.461 | 1.262–1.690 | < 0.0001 |
| Women BMI 25–29.9   | 2988 | 56.0 | 1.076 | 0.940–1.231 | 0.288 |
| Women BMI ≥ 30      | 3095 | 60.9 | 1.321 | 1.151–1.515 | < 0.0001 |

BMI body mass index (kg/m²); CI confidence interval; OR odds ratio of the association between obesity/overweight and uncontrolled hypertension compared to subgroups of men and women with BMI less than 25 kg/m²; P probability (association of uncontrolled hypertension and obesity and overweight at the baseline, compared to subgroups of men and women with BMI less than 25 kg/m² cohorts, compared using Chi-square test)
BMI decrease and hypertension control
Logistic regression show that in the cohorts of obese and overweight men and women at the baseline, BMI decrease during the follow-up by at least 1 kg/m² was inversely associated with the presence of uncontrolled hypertension at the end of the follow-up. The logistic regression used baseline age, systolic blood pressure (SBP), diastolic blood pressure (DBP), creatinine, and doses of antihypertensive therapy at the beginning and at the end of the follow-up as possible confounding variables (Table 3). Weight loss surrogated by BMI decrease resulted in a lower risk of suffering from uncontrolled hypertension in obese and overweight patients, with the strongest association observed in the cohort of obese men, followed by that of obese women. The BMI decrease had no significant effect on AH control in men and women with BMI less than 25 kg/m² (Table 3).

BMI increase and hypertension control
Logistic regression analysis shows that in the cohorts of men and women with obesity and overweight, BMI increase by at least 1 kg/m² during the follow-up was positively associated with uncontrolled hypertension at the end of the follow-up. The logistic regression used baseline age, SBP, DBP, creatinine, and doses of antihypertensive therapy at the beginning and at the end of the follow-up as possible confounding variables (Table 4). In the cohorts of men and women with BMI < 25 kg/m², a slight trend was observed, but association was not statistically significant (Table 4). The highest odds ratio was observed in the cohort of overweight men, followed by that of overweight women (Table 4).

### Table 3: Association between BMI decrease by at least 1 kg/m² during the 1-year follow-up and the risk of uncontrolled hypertension at the end of the follow-up by logistic regression

| BMI at the baseline | Gender | p     | OR    | 95% CI          |
|---------------------|--------|-------|-------|-----------------|
| BMI < 25            | Men    | 0.397 | 0.771 | 0.423–1.406     |
|                     | Women  | 0.242 | 0.743 | 0.451–1.223     |
| BMI 25–29.9         | Men    | < 0.05| 0.804 | 0.636–0.997     |
|                     | Women  | < 0.05| 0.732 | 0.568–0.937     |
| BMI ≥ 30            | Men    | < 0.001| 0.586 | 0.481–0.713     |
|                     | Women  | < 0.001| 0.730 | 0.611–0.876     |

BMI body mass index (kg/m²); CI confidence interval; OR odds ratio of the association between BMI decrease and uncontrolled hypertension at the end of the follow-up (compared to cohorts with no significant BMI change); p probability (association assessed using binary logistic regression, age, baseline systolic and diastolic blood pressure, creatinine, and number of minimal effective doses of antihypertensive drugs at the beginning and at the end of the follow-up were included in the analysis as possible confounders)

### Table 4: Association between BMI increase by at least 1 kg/m² during the 1-year follow-up and the risk of uncontrolled hypertension at the end of the follow-up by logistic regression

| BMI at the baseline | Gender | p     | OR    | 95% CI          |
|---------------------|--------|-------|-------|-----------------|
| BMI < 25            | Men    | 0.131 | 1.383 | 0.908–2.104     |
|                     | Women  | 0.247 | 1.166 | 0.846–1.607     |
| BMI 25–29.9         | Men    | < 0.0001| 1.901 | 1.463–2.470     |
|                     | Women  | < 0.0001| 1.647 | 1.304–2.080     |
| BMI ≥ 30            | Men    | < 0.001| 1.471 | 1.087–1.991     |
|                     | Women  | < 0.001| 1.422 | 1.104–1.833     |

BMI body mass index (kg/m²); CI confidence interval; OR odds ratio of the association between BMI increase and uncontrolled hypertension at the end of the follow-up (compared to cohorts with no significant BMI change); p probability (association assessed using binary logistic regression, age, baseline systolic and diastolic blood pressure, creatinine, and number of minimal effective doses of antihypertensive drugs at the beginning and at the end of the follow-up were included in the analysis as possible confounders)

### Discussion
This prospective follow-up of patients in primary care for a duration of 1 year has revealed that changes in the body weight in terms of BMI variations above 1 kg/m² influence the effectiveness of antihypertensive therapy. There is a large body of evidence linking weight changes to changes in BP. However, no comprehensive study has been conducted before now to explore this link, and the role of weight management in the complex antihypertensive therapy in primary care is yet to be determined. Our results emphasize the significance of BW control in improving the efficacy of antihypertensive treatment in primary care and highlights not just the benefits of weight reduction but also the benefits of, at least, maintaining a stable weight over weight gain.

### Weight loss and hypertension control
In our study, in obese men and women, BMI decrease during the follow-up by at least 1 kg/m² was inversely associated with uncontrolled hypertension at the end of the follow-up. The odds ratio for uncontrolled hypertension was lower in obese men than in obese women, indicating a stronger association in men. This association was observed also in the groups of overweight men and women, but the odds ratios were higher in patients with obesity. In men and women with BMI less than 25 kg/m², no effect on AH control has been observed. Thus, weight reduction in obese patients seems to bring a greater benefit in terms of achieving hypertension control compared to overweight patients and is of greatest importance in obese men. Previous studies indicate an association between weight loss and reduction of SBP and DBP. A meta-analysis of 25 studies found a linear relationship between weight loss and blood pressure and showed that the decrease in weight by 1 kg is associated
with approximately 1 mmHg decline in SBP [12]. A large prospective study (The Trial of Hypertension Prevention) with more than 500 prehypertensive individuals assigned to weight loss programme showed not just a significant decrease in SBP and DBP but also a significantly lower proportion of hypertensive patients in the treatment arm at the end of the follow-up [14].

Weight increase and hypertension control
BMI increase was positively associated with poor hypertension control at the end of the follow-up in obese and overweight patients. In overweight men and women, higher odds ratios were observed, indicating a stronger association than in obese individuals. The effect of weight increase on BP and the linear association between weight increase and SBP have been described [9]. In a more recent study, weight gain during 1-year follow-up was associated with an increase in SBP and DBP in young adults regardless of baseline BMI [11]. On the basis of our findings, it can be supposed that even maintenance of a stable weight is beneficial compared to weight gain in terms of appropriate hypertension control. Since obesity is associated also with other negative metabolic effects, like the atherogenic changes in fasting and postprandial lipoprotein profile, weight management should be a crucial part of the complex treatment of patients with arterial hypertension [20].

Pathophysiologic background
The potential pathophysiologic implications of adiposity on blood pressure increase and poor BP control have been identified. Most of them are linked to water and salt metabolism and regulation of sodium excretion. Obesity leads to the up-regulation of renin–angiotensin–aldosterone one axis and sodium and fluid retention [21, 22]. Moreover, leptin, the hormone produced by adipose tissue, is excessively secreted in obesity. This adipokine stimulates the sympathetic sensitivity of the kidney, which may lead to excessive sodium and fluid retention [23]. This effect is probably aldosterone dependent [24]. Furthermore, insulin resistance with hyperinsulinemia induced by abdominal obesity may attenuate renal sodium excretion [25, 26]. On the other hand, the concentration of ghrelin, the hormone produced by the gastric mucosa during fasting period that stimulates the excretion of sodium, is lowered in obese patients and rises during weight loss. In animals, ghrelin increase results in the reduction of BP [27]. Increase in ghrelin concentration stimulated by weight loss might contribute to the improvement of BP control. Additionally, obesity is associated with histologic and macroscopic kidney abnormalities, which may alter the kidney competence to maintain sodium and fluid homeostasis. However, it is supposed that these renal alterations are reversible and could be improved by weight loss [28].

Limitations of the study
Participants of our study did not undergo a controlled weight reduction programme, since the study was only observational in nature. Therefore, it was not possible to quantify the participation of patients in these non-pharmacologic strategies, such as diet, salt intake, and regular physical activity changes. To minimize this effect, general practitioners were instructed to educate patients about non-pharmacologic means of blood pressure management equally.

In order to minimize the effect of comorbidities that can lead to undesirable loss of weight, the patients with known history of oncologic disease (except in the case of total remission), pregnancy, thyrotoxicosis, liver cirrhosis, malabsorption syndrome, and end-stage kidney disease were excluded. However, there was a possibility that in some patients, these conditions might develop during the follow-up. Also, the possibility of significant worsening of glomerular filtration rate during the follow-up was not ruled out.

Patients in our study differ in terms of antihypertensive therapy. Moreover, the pharmacological therapy was modified in a substantial number of patients during the follow-up. To decrease the effect of possible differences in pharmacological therapy as a confounding factor, the doses of antihypertensive therapies administered at the baseline and at the end of the follow-up were included in the logistic regression analysis as a possible confounder. All the patients were followed up on a regular basis of 3 months, and the general practitioners were strictly instructed to provide the same level of medical attention to each patient. However, there is a possibility of difference in the frequency of therapy modification.

Also, the duration of the follow-up period should be considered. Our patients were observed for the period of 1 year; thus, it was not possible to assess the long-term effect of weight loss. A previous study on obese patients who underwent bariatric procedure has shown that BP increased again on pre-surgery values during 8-year follow-up [29]. However, another study not using bariatric surgery has shown that the effect of weight loss lasts for 3 years minimally if the weight remains at least 4% lower than the baseline weight [14].

Most previous studies used body weight change as an indicator of weight loss. We used delta BMI rather than delta body weight, because BMI is a function of body adiposity [30].

Conclusion
In our large observational prospective study, it has been shown that BW reduction by at least 1 kg/m² was associated with lower risk of uncontrolled hypertension at the end of 1-year follow-up in patients with obesity and
overweight. This emphasizes the importance of BW control in the management of cardiovascular risk in patients with arterial hypertension, and it should be considered as an unavoidable recommendation in the complex treatment of arterial hypertension in obese and overweight individuals. On the other hand, weight increase by at least 1 kg/m² during 1-year follow-up enhanced the risk of uncontrolled hypertension compared to maintaining approximately the same weight. It is suggested that weight loss or at least stabilization of BW may improve the control of hypertension in obese hypertensics and in overweight hypertensive patients.

Abbreviations
BMI: body mass index; BP: blood pressure; BW: body weight; DBP: diastolic blood pressure; SBP: systolic blood pressure; OR: odds ratio; RR: relative risk.

Authors’ contributions
PS drafted the manuscript and participated in the data analysis and interpretation. AD and JG were critical participants in the study development and provided inputs within their respective areas of expertise during analysis and manuscript drafting and revision. MC and MB participated in the data analysis. FS was the main manuscript reviser, participated in the data analysis and interpretation as well as in the development of the study design. All authors were involved in writing the paper. All authors read and approved the final manuscript.

Author details
1 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava, Špitálska 24, 813 72 Bratislava, Slovak Republic. 2 Department of Pathophysiology, Faculty of Medicine, Comenius University in Bratislava, Špitálska 24, 813 72 Bratislava, Slovak Republic.

Acknowledgements
The authors would like to acknowledge all the general practitioners and internists that participated in the Mirror Slovakia Study.

Competing interests
All authors declare that they have no competing interests.

Availability of data and materials
The datasets used and analyzed during the current study are available and could be obtained from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the ethical committee of Ministry of Health of Slovak Republic. All participants signed an informed consent.

Funding
None.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 January 2017 Accepted: 12 October 2017 Published online: 25 October 2017

References
1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.
2. Chiang HH, Tseng FY, Wang CY, Chen CL, Chen YC, See TT, et al. All-case mortality in patients with type 2 diabetes in association with achieved hemoglobin A1c, Systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS ONE. 2014;9:e109501. doi:10.1371/journal.pone.0109501.
3. Simko F, Pecharanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens. 2010;28(Suppl 1):S1–6. doi:10.1097/01.hjh.0000388487.43460.db.
4. Paulis L, Matuskova J, Adamcova M, Pelouch V, Simko J, Krajcirovicova K, et al. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of l-arginine and spironolactone. Acta Physiol. 2008;194:45–55. doi:10.1111/j.1748-1716.2008.01862.x (Epub 2008 Apr 16).
5. Rulope LMA, Dukat A, Böhm M, Lacourcière Y, Gong J, Liefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1253–66. doi:10.1016/S0140-6736(09)61968-6 (Epub 2010 Mar 16).
6. Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M, Mokdad AH, Lozano R, Murray CJ, et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014;92:10–9. doi:10.2471/BLT.13.121954.
7. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81. doi:10.1016/S0140-6736(14)60460-8 (Epub 2014 May 29).
8. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14. doi:10.1001/jama.2014.732.
9. Hall JE, Crook ED, Jones DW, Wolford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324:127–37.
10. Re RN. Obesity-related hypertension. Ochsner J. 2009;9:133–6.
11. Andrade FCD, Vazquez-Vidal I, Flood T, et al. One-year follow-up changes in weight are associated with changes in blood pressure in young mexican adults. Public Health. 2012;126:535. doi:10.1016/j.puhe.2012.02.005.
12. Neter JE, Stam BE, Kok FJ, Grobbee DE, Gelseijne JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.
13. Whelton PK, Appel LJ, Charleston J, Dalcin AT, Ewart C, Fried L, Kaidy D, Klag MJ, Kumanyika S, Steffen L, Walker WG. The effects of nonpharma- cologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention phase 1. JAMA. 1992;267:1213–20.
14. Stevens VI, Obzaranek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1–11.
15. Siebenhofer A, Jetter K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013;3:CD007654.
16. Symonds B. Blood pressure of healthy men and women. JAMA. 1923;8:232–6.
17. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:908–77.
18. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the manage- ment of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1007/s10559-013-2526-9.
19. State Institute for Drug Control. The SIDG register. http://www.sukl.eu/. Accessed 28 Aug 2015.
20. Sabaka P, Kruzliak P, Gaspar L, Caprná M, Bendzala M, Balaz D, et al. Postprandial changes of lipoprotein profile: effect of abdominal obesity. Lipids Health Dis. 2013;12:179. doi:10.1186/1476-511X-12-179.
21. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13:136–49. doi:10.1111/j.1467-789X.2011.00942.x (Epub 2011 Oct 31).
22. Thethi T, Kamiyama M, Kobori H. The Link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14:160–9. doi:10.1007/s11906-012-0245-z.
23. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17:1949–53.
24. Huby AC, Otvos L Jr, Belin de Chantemèle EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension. 2016;67:1020–8. doi:10.1161/HYPERTENSIONAHA.115.06642 (Epub 2016 Mar 7).
25. Sechi M, Leonardo A. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens. 1999;17:1229–37.
26. Zhou M-S, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metab Synd. 2014;6:12. doi:10.1186/s11758-5996-6-12.
27. Mao Y, Tokudome T, Kishimoto I. Ghrelin and blood pressure regulation. Curr Hypertens Rep. 2016;18:15. doi:10.1007/s11906-015-0622-5.
28. D’Agati VD, Chagnac A, de Vries AP, Levi M, Porro R, Herman-Edelstein M, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12:453–71. doi:10.1038/nrneph.2015.87.
29. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differential long-term effects of intentional weight loss on diabetes and hypertension. Hypertension. 2000;36:20–5.
30. Shah NR, Braverman ER. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS ONE. 2012;7(4):e33308. doi:10.1371/journal.pone.0033308.